Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyInactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells.Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.MYC is a critical target of FBXW7Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatmentSGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance.Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.BET bromodomain inhibitors synergize with ATR inhibitors in melanoma in melanomaBET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.c-MYC-induced genomic instability.
P2860
Q26745686-8340057E-7983-4856-9DA7-DB09AED3DC21Q33578581-101F836E-B6D9-4BF0-82E0-F50ED6E8D26FQ33649555-A993FED5-A827-4CED-9961-D41F4F0EAB65Q34307356-25911DF9-5AC4-41B9-B154-C54398B7E4BAQ35228809-9EA935BA-8602-4480-BBC5-6BA31E78FD03Q35550234-909DCE66-B00D-4F63-9824-1B2553BE46A9Q36392155-DD27CD83-1F23-4CC4-915F-17FD26D78C9EQ37188977-B297ED27-2551-4DDD-B95F-86267B0FF5F0Q37988976-8B46AACE-B99A-4C40-9FF8-66C01D17B022Q38608688-349CC59C-E581-42F1-96C6-A6D88D4C4D12Q38630705-C35516D5-2970-4AAB-AC17-C34EBC4A54E3Q38799987-EA583416-F0FC-408C-B114-64E7CF2BE18DQ39169663-44C2C72D-4BB2-41B4-B69B-2680FEB8B54DQ42127661-25E8F459-FCA5-4595-A919-951707749601
P2860
Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Chk2 deficiency in Myc overexp ...... mbination with PARP inhibition
@ast
Chk2 deficiency in Myc overexp ...... mbination with PARP inhibition
@en
Chk2 deficiency in Myc overexp ...... mbination with PARP inhibition
@nl
type
label
Chk2 deficiency in Myc overexp ...... mbination with PARP inhibition
@ast
Chk2 deficiency in Myc overexp ...... mbination with PARP inhibition
@en
Chk2 deficiency in Myc overexp ...... mbination with PARP inhibition
@nl
prefLabel
Chk2 deficiency in Myc overexp ...... mbination with PARP inhibition
@ast
Chk2 deficiency in Myc overexp ...... mbination with PARP inhibition
@en
Chk2 deficiency in Myc overexp ...... mbination with PARP inhibition
@nl
P2093
P2860
P3181
P356
P1433
P1476
Chk2 deficiency in Myc overexp ...... mbination with PARP inhibition
@en
P2093
Andreas Höglund
Jonas A Nilsson
Kerstin Strömvall
Linus Plym Forshell
Yongmei Li
P2860
P304
P3181
P356
10.4161/CC.10.20.17887
P407
P577
2011-10-15T00:00:00Z